Brief: Annexon Announces Clinical And Regulatory Progress For Anx005 Pivotal Program In Guillain-Barré Syndrome (GBS)

Annexon

10/10/2023 12:36

Oct 10 (Reuters) - Annexon Inc  ANNX.O :
    * ANNEXON ANNOUNCES CLINICAL AND REGULATORY PROGRESS FOR
ANX005
PIVOTAL PROGRAM IN GUILLAIN-BARRÉ SYNDROME (GBS)
    * ANNEXON INC- ON TRACK TO REPORT PIVOTAL DATA IN FIRST HALF
OF
2024
    * ANNEXON INC - ANX005 GRANTED ORPHAN DRUG DESIGNATION BY
EUROPEAN
MEDICINES AGENCY FOR TREATMENT OF GBS
    * ANNEXON INC - TARGET ENROLLMENT ACHIEVED IN PHASE 3
PIVOTAL
STUDY OF ANX005 IN GBS REPRESENTING CO'S THIRD EXECUTED CLINICAL
STUDY IN GBS

Source text for Eikon:  ID:nGNXbVzWG7 
Further company coverage:  ANNX.O 

 ((Reuters.Briefs@thomsonreuters.com;))